Mitoxantrone Hydrochloride

Anthracenedione antineoplastic Antineoplastic agent, DNA intercalating agent

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog IV 5-6 mg/m² Every 3 weeks Duration: As per protocol (e.g., 4-6 cycles)
Notes: Administer as a slow IV infusion over 5-15 minutes. Dose may be adjusted based on hematologic tolerance.
Cat IV 5-6 mg/m² Every 3 weeks Duration: As per protocol
Notes: Cats may be more sensitive to myelosuppression; consider lower starting dose (5 mg/m²) and monitor CBC closely.
Horse Intralesional 0.5-1 mg per lesion Every 2-3 weeks Duration: Until resolution
Notes: Limited data; use with caution. Not a standard systemic treatment.

Clinical Indications & Species Uses

General Indications
  • Antineoplastic agent for various tumors; immunomodulatory in autoimmune diseases (not standard in veterinary)
Dog (Canine)
  • Lymphoma (as part of combination protocols)
  • Mammary carcinoma
  • Squamous cell carcinoma
  • Transitional cell carcinoma of the bladder
  • Various sarcomas
Cat (Feline)
  • Lymphoma
  • Mammary carcinoma
  • Squamous cell carcinoma
  • Fibrosarcoma

Pharmacology & Mechanism of Action

Drug Class: Anthracenedione antineoplastic | Pharmacological Group: Antineoplastic agent, DNA intercalating agent

Mechanism of Action: Mitoxantrone is an anthracenedione derivative that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA replication and RNA synthesis. It also has immunomodulatory effects, including inhibition of B cell, T cell, and macrophage proliferation, and suppression of antigen presentation. Its cytotoxic effects are cell cycle non-specific, but it is most active in the S phase.

Pharmacodynamics: Mitoxantrone exerts its antineoplastic effects by binding to DNA and interfering with the enzyme topoisomerase II, resulting in DNA double-strand breaks and cell death. It also generates free radicals, contributing to its cytotoxic activity. In addition, it has anti-inflammatory and immunomodulatory properties, which are exploited in the treatment of autoimmune diseases such as multiple sclerosis in humans. In veterinary medicine, it is used primarily for its antineoplastic activity against various tumors.

⚡ Pharmacokinetics Summary

Absorption: Mitoxantrone is not absorbed orally and must be administered intravenously. After IV administration, it rapidly distributes into tissues.
Distribution: Mitoxantrone has a large volume of distribution, with extensive tissue binding, particularly to the liver, spleen, heart, and bone marrow. It crosses the blood-brain barrier poorly. Protein binding is approximately 78% in humans, but species-specific data are limited.
Metabolism: Mitoxantrone is extensively metabolized in the liver via reduction and conjugation, forming inactive metabolites. The metabolism is primarily hepatic, and hepatic impairment may alter drug clearance.
Excretion: Mitoxantrone is excreted primarily in the bile and feces, with a smaller amount excreted renally. In dogs, the terminal half-life is approximately 1.5 to 2.5 hours, but the drug persists in tissues for a long time due to extensive tissue binding.
Half-Life: Dog: 1.5-2.5 hours (terminal); Cat: approximately 1-2 hours; Human: 2.3-13 hours (terminal).
Bioavailability: Oral bioavailability is negligible; must be administered intravenously.
Protein Binding: Approximately 78% in humans; species-specific data not well established.

Available Formulations & Strengths

Injectable Solution 2 mg/mL (as base) (IV)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to mitoxantrone
  • Severe myelosuppression (neutrophils < 1500/µL, platelets < 50,000/µL)
  • Severe hepatic impairment
  • Severe cardiac disease or prior anthracycline therapy with cardiotoxicity
  • Pregnancy (teratogenic)
  • Lactation (may be excreted in milk)
Warnings & Clinical Precautions:
  • Myelosuppression is dose-limiting; monitor CBC closely before and after administration.
  • Cardiotoxicity may occur, especially with cumulative doses > 120-160 mg/m² in dogs; perform echocardiography before and during treatment.
  • Extravasation can cause severe tissue necrosis; ensure proper IV catheter placement.
  • Use with caution in patients with pre-existing renal or hepatic disease.
  • Immunosuppression may increase risk of infections.
  • Handle with caution; wear gloves and protective equipment during preparation and administration.
  • Do not use in animals intended for breeding.

Adverse Effects & Reactions

Common:

  • Myelosuppression (neutropenia, thrombocytopenia, leukopenia)
  • Gastrointestinal effects (nausea, vomiting, diarrhea)
  • Anorexia
  • Lethargy
  • Alopecia (mild)

Serious / Severe:

  • Cardiotoxicity (arrhythmias, congestive heart failure)
  • Severe myelosuppression with secondary infections
  • Extravasation injury (tissue necrosis)
  • Hepatotoxicity
  • Renal toxicity (rare)

Rare:

  • Anaphylaxis
  • Secondary leukemia (in humans; rare in animals)
  • Pulmonary fibrosis

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other myelosuppressive agents (e.g., cyclophosphamide, doxorubicin) Additive myelosuppression; increased risk of severe bone marrow suppression. High
Anthracyclines (e.g., doxorubicin) Increased risk of cardiotoxicity due to cumulative cardiotoxic effects. High
Hepatotoxic drugs (e.g., azathioprine, ketoconazole) Increased risk of hepatotoxicity; monitor liver enzymes. Moderate
NSAIDs Increased risk of gastrointestinal ulceration and bleeding. Moderate
Corticosteroids May increase immunosuppression; monitor for infections. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe myelosuppression (pancytopenia)
  • Cardiotoxicity (arrhythmias, hypotension)
  • Gastrointestinal toxicity (severe vomiting, diarrhea)
  • Hepatotoxicity
  • Renal failure

Emergency Treatment Protocol: There is no specific antidote. Treatment is supportive and symptomatic: hospitalization, IV fluids, antiemetics, antimicrobial therapy for infections, blood transfusions if needed, and cardiac monitoring. Consider granulocyte colony-stimulating factor (G-CSF) for severe neutropenia. In cases of recent overdose, activated charcoal may be considered if oral (not applicable as IV only).

Food Animal Withdrawal Times

Not approved for food animals; no withdrawal times established. Use in food animals is prohibited or extra-label with extended withdrawal periods (e.g., 180 days meat, 7 days milk) as per veterinary discretion.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20°C to 25°C (68°F to 77°F); protect from freezing.

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Store in original carton. Diluted solutions are stable for 24 hours at room temperature or 48 hours under refrigeration.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not approved for veterinary use; approved for human use (e.g., for cancer and multiple sclerosis).

Extra-Label (Off-Label) Use: Mitoxantrone is not FDA-approved for veterinary species; use is extra-label under AMDUCA. Requires a valid veterinarian-client-patient relationship. For food animals, extra-label use is prohibited unless under specific conditions with extended withdrawal times.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Mitoxantrone is a valuable chemotherapeutic agent in veterinary oncology, particularly for lymphoma and various carcinomas. It is often used as a rescue agent or in combination protocols. Key clinical considerations: (1) Administer only intravenously, with care to avoid extravasation; (2) Monitor complete blood counts before and after each dose, typically nadir at 7-10 days; (3) Assess cardiac function (echocardiography) before starting and after cumulative doses; (4) Adjust dose in patients with hepatic impairment; (5) Use with caution in cats due to increased sensitivity to myelosuppression; (6) Provide antiemetic and supportive care as needed. Always follow safe handling guidelines for cytotoxic drugs.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)